The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 21, 2023

Filed:

Oct. 05, 2018
Applicant:

Lonza Ltd., Visp, CH;

Inventors:

Thaddaeus Webster, Rollinsford, NH (US);

Brian Hadley, Dover, NH (US);

Carrie Mason, Brentwood, NH (US);

Colin Jaques, London, GB;

Seshu Tummala, Newburyport, MA (US);

Ruth Christine Rowland-Jones, Chelmsford, GB;

Yonatan Levinson, Silver Spring, MD (US);

Nicholas Uth, Washington, DC (US);

Pankaj Sinha, Alpharetta, GA (US);

Eytan Abraham, Potomac, MD (US);

Assignee:

Lonza Ltd, Visp, CH;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01J 3/44 (2006.01); G01N 21/65 (2006.01); C12M 1/36 (2006.01); C12M 1/34 (2006.01); C12M 1/00 (2006.01); C12N 5/0735 (2010.01); C12N 5/0783 (2010.01); G01N 21/84 (2006.01);
U.S. Cl.
CPC ...
G01J 3/44 (2013.01); C12M 31/08 (2013.01); C12M 41/32 (2013.01); C12M 41/36 (2013.01); C12M 41/48 (2013.01); C12N 5/0606 (2013.01); C12N 5/0636 (2013.01); G01N 21/65 (2013.01); G01N 2021/8411 (2013.01); G01N 2201/129 (2013.01);
Abstract

The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.


Find Patent Forward Citations

Loading…